PHILADELPHIA and NEW YORK, Aug. 3,
2021 /PRNewswire/ -- Chardan Healthcare Acquisition 2 Corp.
(the "Company") announced that the close of business on
Thursday, August 5, 2021, has been
set as the record date for the determination of stockholders
eligible to receive the proxy and vote at the special meeting to be
held to consider and approve the previously announced merger with
Renovacor, Inc., a Delaware
corporation ("Renovacor").
On March 23, 2021, Renovacor and
the Company announced a definitive agreement for a business
combination that would result in Renovacor becoming a publicly
listed company.
A proxy statement, once final, will be mailed together with a
proxy card to the Company's stockholders. The final proxy statement
will include the date, time and location of the annual meeting.
About Chardan Healthcare Acquisition Corp.
CHAQ is a special purpose acquisition company formed for the
purpose of effecting a merger, acquisition, or similar business
combination. CHAQ raised approximately $86.0
million in April 2020 for the
purpose of combining with a public or privately-held operating
business. CHAQ was founded and sponsored by affiliates of Chardan
Capital Markets LLC. CHAQ is Chardan's sixth publicly traded
acquisition vehicle.
About Renovacor
Renovacor is a preclinical stage gene therapy company developing
a pipeline of innovative and proprietary AAV-based gene therapies
for BAG3 gene mutation-associated diseases in areas of high unmet
medical need. Renovacor's therapeutic focus is initially on
cardiovascular disease, with a lead program in BAG3
mutation-associated dilated cardiomyopathy.
https://www.renovacorinc.com
No portion of Renovacor's website is incorporated by reference
into or otherwise deemed to be a part of this press release.
Additional Information and Where to Find It
This document relates to a proposed transaction between
Renovacor and CHAQ. This document does not constitute an offer to
sell or exchange, or the solicitation of an offer to buy or
exchange, any securities, nor shall there be any sale of securities
in any jurisdiction in which such offer, sale or exchange would be
unlawful prior to registration or qualification under the
securities laws of any such jurisdiction. CHAQ intends to file a
proxy statement, which will be sent to all CHAQ and Renovacor
stockholders. CHAQ also will file other documents regarding the
proposed transaction with the SEC. BEFORE MAKING ANY VOTING
DECISION, INVESTORS AND SECURITY HOLDERS OF CHAQ AND RENOVACOR ARE
URGED TO READ THE PROXY STATEMENT, AS MAY BE AMENDED OR
SUPPLEMENTED FROM TIME TO TIME, AND ALL OTHER RELEVANT DOCUMENTS
FILED OR THAT WILL BE FILED WITH THE SEC IN CONNECTION WITH THE
PROPOSED TRANSACTION AS THEY BECOME AVAILABLE BECAUSE THEY WILL
CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND
THE PARTIES THERETO.
Investors and security holders will be able to obtain free
copies of the proxy statement and all other relevant documents
filed or that will be filed with the SEC by CHAQ through the
website maintained by the SEC at www.sec.gov. In addition, the
documents filed by CHAQ may be obtained free of charge from CHAQ's
website at https://www.chardanhealthcarespac.com/ or by
written request to CHAQ at Chardan Healthcare Acquisition 2 Corp.,
17 State Street, 21st Floor, New York,
NY 10004.
Participants in the Solicitation
CHAQ and Renovacor and their respective directors and officers
may be deemed to be participants in the solicitation of proxies
from CHAQ's stockholders in connection with the proposed
transaction. Information about CHAQ's directors and executive
officers and their ownership of CHAQ's securities is set forth in
CHAQ's filings with the SEC, including CHAQ's Annual Report on Form
10-K for the fiscal year ended December 31,
2020, which was filed with the SEC on March 4, 2021. To the extent that holdings of
CHAQ's securities have changed since the amounts printed in CHAQ's
Annual Report on Form 10-K for the fiscal year ended December 31, 2020, which was filed with the SEC
on March 4, 2021, such changes have
been or will be reflected on Statements of Change in Ownership on
Form 4 filed with the SEC. Additional information regarding the
interests of those persons and other persons who may be deemed
participants in the proposed transaction may be obtained by reading
the proxy statement regarding the proposed transaction when it
becomes available. You may obtain free copies of these documents as
described in the above paragraph.
Forward Looking Statements
This document contains certain forward-looking statements within
the meaning of the "safe harbor" provisions of the United States
Private Securities Litigation reform Act of 1995, as amended, with
respect to the proposed transaction between Renovacor and CHAQ,
including statements regarding the benefits of the transaction, the
anticipated timing of the transaction, Renovacor's products under
development and the markets in which it intends to operate, and
Renovacor's projected future results. These forward-looking
statements generally are identified by the words "believe,"
"project," "expect," "anticipate," "estimate," "intend,"
"strategy," "future," "opportunity," "plan," "may," "should,"
"will," "would," "will be," "will continue," "will likely result,"
and similar expressions. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this document, including but not
limited to: (i) the risk that the transaction may not be completed
in a timely manner or at all, which may adversely affect the price
of CHAQ's securities, (ii) the risk that the transaction may not be
completed by CHAQ's business combination deadline and the potential
failure to obtain an extension of the business combination deadline
if sought by CHAQ, (iii) the failure to satisfy the conditions to
the consummation of the transaction, including the adoption of the
agreement and plan of merger by the stockholders of CHAQ and
Renovacor, the satisfaction of the minimum trust account amount
following redemptions by CHAQ's public stockholders and the receipt
of certain governmental and regulatory approvals, (iv) the lack of
a third party valuation in determining whether or not to pursue the
proposed transaction, (v) the occurrence of any event, change or
other circumstance that could give rise to the termination of the
agreement and plan of merger, (vi) the effect of the announcement
or pendency of the transaction on Renovacor's business
relationships, performance, and business generally, (vii) risks
that the proposed transaction disrupts current plans of Renovacor
and potential difficulties in Renovacor employee retention as a
result of the proposed transaction, (viii) the outcome of any legal
proceedings that may be instituted against Renovacor or against
CHAQ related to the agreement and plan of merger or the proposed
transaction, (ix) the ability to maintain the listing of CHAQ's
securities on the New York Stock Exchange, (x) the price of CHAQ's
securities may be volatile due to a variety of factors, including
changes in the competitive and highly regulated industries in which
Renovacor plans to operate, variations in performance across
competitors, changes in laws and regulations affecting Renovacor's
business and changes in the combined capital structure, (xi) the
ability to implement business plans, forecasts, and other
expectations after the completion of the proposed transaction, and
identify and realize additional opportunities, (xii) the risk of
downturns in the highly competitive additive manufacturing
industry, (xiii) the impact of legislative, regulatory, competitive
and technological changes to Renovacor's business or product
candidates, (xiv) expectations for future studies and clinical
trials, the timing and potential outcomes of clinical studies and
interactions with regulatory authorities, and (xv) expectations
regarding BAG3 programs. The foregoing list of factors is not
exhaustive. You should carefully consider the foregoing factors and
the other risks and uncertainties described in the "Risk Factors"
section of CHAQ's Annual Reports on Form 10-K, Quarterly Reports on
Form 10-Q and proxy statement discussed above and other documents
filed by CHAQ from time to time with the SEC. These filings
identify and address other important risks and uncertainties that
could cause actual events and results to differ materially from
those contained in the forward-looking statements. Forward-looking
statements speak only as of the date they are made. Readers are
cautioned not to put undue reliance on forward-looking statements,
and Renovacor and CHAQ assume no obligation and do not intend to
update or revise these forward-looking statements, whether as a
result of new information, future events, or otherwise. Neither
Renovacor nor CHAQ gives any assurance that either Renovacor or
CHAQ will achieve its expectations.
Temple University Disclosure
Statement
Dr. Arthur Feldman is a founder
and director of Renovacor and holds equity interest in Renovacor.
Temple University has significant
financial interests in the technology licensed to Renovacor. The
financial interests are being managed in accordance with
Temple University's institutional
policy. Questions about Temple
University's policy can be directed to
coitemple@temple.edu.
CHAQ contact:
Jonas
Grossman
CEO
Chardan Healthcare Acquisition 2 Corp.
212-920-9000
jonas@chardanspac2.com
Renovacor contact:
Magdalene
Cook, MD
CEO
Renovacor
info@renovacorinc.com
Media contact:
Tom
Rozycki
Prosek Partners
646-818-9208
trozycki@prosek.com
View original
content:https://www.prnewswire.com/news-releases/chardan-healthcare-acquisition-2-corp-announces-record-date-for-stockholders-eligible-to-vote-on-merger-301347592.html
SOURCE Chardan Healthcare Acquisition Corp.
